IMM-101
IMM-101 is an immunomodulatory drug that is being studied to see if it is useful in chemotherapy.[1] It consists of heat-killed Mycobacterium obuense bacteria. It may have relatively few side effects compared to other drugs.[2][3]
| Clinical data | |
|---|---|
| Other names | Mycobacterium obuense (heat-killed) |
| Identifiers | |
| UNII | |
References
- Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, et al. (September 2016). "Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer". British Journal of Cancer. 115 (7): 789–796. doi:10.1038/bjc.2016.271. PMC 5046215. PMID 27599039.
- Boseley S (6 September 2016). "New drug 'wakes up' immune system to fight one of deadliest cancers". The Guardian.
- Dalgleish V. "A trial looking at a new type of immunotherapy for cancer of the pancreas that can't be removed with surgery". Cancer Research UK.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.